(SGGH) To Acquire World’s Largest Independent Aluminum Recycler

SHERMAN OAKS, Calif. and CLEVELAND, Oct. 18, 2014  — Signature Group Holdings, Inc. (“Signature” or the “Company”) (OTCQX: SGGH) announced today that it has entered into a definitive stock purchase agreement to acquire the Global Recycling and Specification Alloys (“GRSA”) business of privately-held Aleris Corporation (“Aleris”) for$525 million. The Board of Directors of Signature unanimously approved the proposed transaction. The transaction is subject to customary closing conditions, including regulatory approvals and clearance under the Hart-Scott Rodino Antitrust Improvements Act.

This marks the entry of Signature into the resurgent aluminum market in North America and Europe. GRSA, the largest independent aluminum recycler in the world, is positioned to take advantage of improving fundamentals reshaping global aluminum markets. Sectors such as automotive, aerospace, packaging, building and construction are all experiencing increased aluminum consumption.  The automotive sector, in particular, is consuming more aluminum as government mandates require reduced carbon emissions and compel auto manufacturers to increase fuel efficiency.

“This deal is transformative for Signature in an industry I know well,” said Craig Bouchard, Chairman and Chief Executive Officer of Signature. “GRSA is the low-cost producer and clear market leader on two continents, with strong growth prospects and a sustainable competitive advantage.  We are particularly pleased to inherit a blue chip customer base.  This transaction fulfills a promise made to our stockholders to seek large, accretive, well-valued acquisitions.  It is an important step as we continue to build Signature into a significant and profitable company.”

Signature expects to name Terry Hogan, currently senior vice president and leader of Aleris’ Recycling and Specification Alloys business in North America, as president of the GRSA business effective upon closing the acquisition. Russell Barr, vice president and leader of Aleris’ recycling business inEurope is expected to serve as executive vice president, Europe.  “Terry and Russell are excellent managers and leaders with a strong team that is scalable to a larger platform,” stated Bouchard.

Global recycled aluminum consumption is projected to grow 6.7% a year over the next decade, compared to primary aluminum consumption at 4.5%, according to Freedonia Group.

GRSA is the global market leader in aluminum recycling, converting aluminum scrap and dross into usable metal and specification alloys in molten, ingot and other forms.

For the twelve-month period ended June 30, 2014, Aleris reports that GRSA’s earnings before interest, taxes, depreciation and amortization, on an adjusted, stand-alone basis (“Adjusted EBITDA”) were$74.9 million. Also reported by Aleris, GRSA’s Adjusted EBITDA during the quarter endedSeptember 30, 2014 is expected to be$4.6 million to $7.6 million higher than the Adjusted EBITDA in the quarter endedSeptember 30, 2013.  GRSA’s third quarter 2014 results are estimates and subject to changes based on Aleris management’s final review of financial results during the period.

Approximately 65% of GRSA’s business is conducted in North America, with 35% inEurope. GRSA operates a total of twenty-four facilities across six countries.

Transaction Details

Under the terms of the stock purchase agreement, Signature will acquire GRSA for a purchase price of$525 million comprised of $495 million in cash and $30 million in preferred stock in Signature. The purchase price represents a multiple of approximately 6.5 times GRSA’s Adjusted EBITDA as described above using the midpoint of the estimated improvements in third quarter results.

Signature expects to finance the acquisition with a combination of cash on hand, and the net proceeds from debt and equity financings. This includes the issuance of approximately $300 million of senior secured bonds in a private placement to qualified institutional buyers and certain non-U.S. persons, as well as a registered offering of Signature’s common stock, and a registered stapled rights offering of additional shares of its common stock to Signature stockholders at a date to be determined. A portion of the rights offering will be backstopped by Zell Credit Opportunities Fund, L.P., an affiliate of Equity Group Investments, a private investment firm founded bySam Zell. In connection with the transaction, Goldman Sachs will lead a committed bridge financing with Deutsche Bank. General Electric Capital Corporation will provide a$175 million asset-based lending facility to finance the growth of the company. Those commitments are contingent on the satisfaction of standard conditions.

Deutsche Bank Securities, Inc. acted as exclusive financial advisor, and Crowell & Moring acted as legal advisor, to Signature. Credit Suisse and KeyBanc Capital Markets, Inc. acted as financial advisors, and Fried Frank acted as legal advisor, to Aleris.

Signature will host a conference call for investors at 8:30am, Eastern Time, Tuesday, October 21, 2014. For call-in details, visit the Company’s website at www.signaturegroupholdings.com <http://www.signaturegroupholdings.com/>.

This press release does not constitute an offer of any securities for sale.  Any senior secured notes to be offered in the private placement referenced above will not be and have not been registered under the Securities Act of 1933, as amended, and may not be offered or sold inthe United States absent registration or an applicable exemption from registration requirements.  No offer to buy any common stock of Signature, including pursuant to any stapled rights offering, can be accepted and no part of the purchase price can be received until the registration statement has become effective, and any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date.

Global Recycling and Specification Alloys

GRSA, headquartered in Cleveland, Ohio represents approximately 30% of Aleris’ total revenues at$1.5 billion. In 2013, the business shipped 1.2 million tonnes of recycled aluminum.  GRSA employs approximately 1,600 people at twenty-four facilities inNorth America and Europe, and serves more than 300 customers worldwide. AsNorth America and Europe’s leader in third party recycling, GRSA is poised to take advantage of many positive fundamentals in the industry.  With leadership in specialty services, such as the delivery of aluminum in molten form, GRSA has the expertise and operational flexibility to grow its market share even further.

About Signature Group Holdings, Inc.

Signature is a North America-based holding company seeking to invest its capital in large, well-managed and consistently profitable businesses concentrated primarily in the U.S. industrial and commercial marketplace. Signature has significant capital resources, and federal net operating loss tax carryforwards of nearly$900 million. For more information about Signature, visit its corporate website atwww.signaturegroupholdings.com <http://www.signaturegroupholdings.com>.

Cautionary Statement Regarding Forward-Looking Statements

This release contains forward-looking statements, which are based on our current expectations, estimates, and projections about the Company’s and GRSA’s businesses and prospects, as well as management’s beliefs, and certain assumptions made by management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “should,” “will,” and variations of these words are intended to identify forward-looking statements. Such statements speak only as of the date hereof and are subject to change. The Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason. These statements include, but are not limited to, statements about the Company’s and GRSA’s expansion and business strategies; the Company’s ability to satisfy the conditions to the acquisition of GRSA and the related financings, and to ultimately consummate the GRSA acquisition; anticipated growth opportunities; the amount of capital-raising necessary to achieve those strategies, as well as future performance, growth, operating results, financial condition and prospects. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Accordingly, actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Important factors that may cause such a difference include, but are not limited to the Company’s ability to successfully identify, consummate and integrate the acquisitions of GRSA and/or other businesses; changes in business or other market conditions; the difficulty of keeping expense growth at modest levels while increasing revenues; the Company’s ability to successfully defend against current and new litigation matters: as well as demands by investment banks for defense, indemnity, and contribution claims; obtaining the expected benefits of the reincorporation; the Company’s ability to access and realize value from its federal net operating loss tax carryforwards; and other risks detailed from time to time in the Company’s Securities and Exchange Commission filings, including but not limited to the most recently filed Annual Report on Form 10-K and subsequent reports filed on Forms 10-Q and 8-K.

Media Contact: Dan Wilson, Ogilvy+1-212-880-5346

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES

A non-GAAP financial measure is a numerical measure of historical or future financial performance, financial position or cash flows that excludes amounts, or is subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measure calculated and presented in accordance with GAAP in the balance sheets, statements of operations, or statements of cash flows; or includes amounts, or is subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measures so calculated and presented. EBITDA and Adjusted EBITDA are not financial measures recognized under GAAP. EBITDA and Adjusted EBITDA are presented and discussed because management believes they enhance the understanding of the financial performance of Signature’s and GRSA’s operations by investors and lenders. As a complement to financial measures recognized under GAAP, management believes that EBITDA and Adjusted EBITDA assist investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude items that may obscure underlying performance and distort comparability. Because EBITDA and Adjusted EBITDA are not measures recognized under GAAP, they are not intended to be presented herein as a substitute for net earnings as an indicator of operating performance. EBITDA and Adjusted EBITDA are primarily performance measurements the Company’s senior management and Board expect to use to evaluate certain operating results.

Signature and Aleris calculate EBITDA and Adjusted EBITDA as earnings before interest, taxes, depreciation and amortization, or EBITDA, which is then adjusted to remove or add back certain items, or Adjusted EBITDA. These items are identified below in the reconciliation of GRSA’s net earnings to EBITDA and Adjusted EBITDA. Net earnings is the GAAP measure most directly comparable to EBITDA and Adjusted EBITDA.

Signature and Aleris’ calculation of EBITDA and Adjusted EBITDA may be different from the calculation used by other companies for non-GAAP financial measures having the same or similar names; therefore, they may not be comparable to other companies.

(HDSN) Reports the EPA’s Issuance of Final Rule on HCFC Allowances

Hudson Technologies, Inc. (NASDAQ: HDSN), announced that on October 16, 2014 the Environmental Protection Agency (EPA) Administrator Gina McCarthy signed the final rule pertaining to allowances for virgin production of HCFCs, primarily R-22, for 2015 through 2019. The final rule, which was the lowest proposed approach, provides for virgin R-22 allowances of approximately 22 million pounds in 2015, 18 million pounds in 2016, 13 million pounds in 2017, 9 million pounds in 2018 and 4 million pounds in 2019, with a final ban on all production effective January 1, 2020.

Kevin Zugibe, Hudson’s Chairman and CEO, stated, “The EPA’s final rule provides much needed clarity to our industry and delivers a significantly more aggressive step down approach for the phase-out of R-22, which we have consistently stated is the best method to achieve an orderly phase-out of virgin R-22 and for the establishment of reclamation as the principal, and ultimately the sole source of supply of R-22. Under the EPA’s more aggressive approach, the 2015 allowances of 22 million pounds represent a nearly 60% reduction from the 2014 levels. As we approach 2020 when virgin R-22 production will be fully eliminated, the reclamation industry will become the primary provider of R-22 to service aftermarket demand. As one of the leading reclaimers in the marketplace, the R-22 phase-out provides a significant, long-term opportunity for Hudson.”

The final rule will become effective on the date of publication in the Federal Register. A pre-publication copy of the rule is available at: http://www.epa.gov/ozone/title6/downloads/CAA_Part_82A_2060_AR04_Final_Rule_Pre-pub_version_for_web_10-16-14.pdf

Mr. Zugibe continued, “Additionally, we are encouraged by last month’s announcement from the Administration related to new executive actions to curtail the production of HFCs, the next generation of refrigerants. We currently reclaim HFCs and have the capabilities to reclaim the next generation products so we are positioned to be a key player in supporting an orderly phase out as that evolves.”

About Hudson Technologies

Hudson Technologies, Inc. is a leading provider of innovative solutions to recurring problems within the refrigeration industry. Hudson’s proprietary RefrigerantSide^® Services increase operating efficiency and energy savings, and remove moisture, oils and other contaminants frequently found in the refrigeration circuits of large comfort cooling and process refrigeration systems. Performed at a customer’s site as an integral part of an effective scheduled maintenance program or in response to emergencies, RefrigerantSide^® Services offer significant savings to customers due to their ability to be completed rapidly and at higher purity levels, and can be utilized while the customer’s system continues to operate. In addition, the Company sells refrigerants and provides traditional reclamation services to the commercial and industrial air conditioning and refrigeration markets. For further information on Hudson, please visit the Company’s web site at www.hudsontech.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained herein which are not historical facts constitute forward-looking statements. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changes in the laws and regulations affecting the industry, changes in the markets for refrigerants (including unfavorable market conditions adversely affecting the demand for, and the price of, refrigerants), the Company’s ability to source refrigerants, regulatory and economic factors, seasonality, competition, litigation, the nature of supplier or customer arrangements which become available to the Company in the future, adverse weather conditions, possible technological obsolescence of existing products and services, possible reduction in the carrying value of long-lived assets, estimates of the useful life of its assets, potential environmental liability, customer concentration, the ability to obtain financing, risks associated with the Company’s joint ventures which include the ability of the parties to perform their obligations under the joint venture agreements, any delays or interruptions in bringing products and services to market, the timely availability of any requisite permits and authorizations from governmental entities and third parties as well as factors relating to doing business outside the United States, including changes in the laws, regulations, policies, and political, financial and economic conditions, including inflation, interest and currency exchange rates, of countries in which the joint ventures may seek to conduct business, the Company’s ability to successfully integrate any assets it acquires from third parties into its operations, and other risks detailed in the Company’s periodic reports filed with the Securities and Exchange Commission. The words “believe”, “expect”, “anticipate”, “may”, “plan”, “should” and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date the statement was made.

(GEGI) Now Current

MANCHESTER, N.H., Oct. 17, 2014  — Management of Genesis Electronics Group, Inc. (OTC Pink:GEGI) announced today that they have completed the requirements and are now listed on Pink Sheet as “Current.” The Company filed a form 15 on October 1, 2014 to terminate being an SEC 1934 Act reporting company and has subsequently filed the necessary disclosures as specified by OTC Markets.

In January of 2014, the Company entered into a stock purchase agreement with Defense Technology Corporation (DTC). DTC was formed in 2007 to bring products to market in areas of personal and collateral protection using unique technology to achieve superior protection products for military personnel and at schools and public facilities. The transaction is expected to close in the 4^th quarter of 2014.

In September of 2014, the Company formed a wholly owned subsidiary, Genesis Mining Corporation, and acquired the assets to a fully developed mineral (gold) company that controls the lease rights and has future purchase rights to 985 acres known as the Osceola Mining District located in Nevada. The company also controls the potential water rights. The property is located in Nevada, 29 miles Southeast of Ely. Additional information will be provided in the Company’s disclosures and follow on releases. www.genesisminingcorp.com

Mr. Raymond Purdon, President & CEO, commented, “We are very excited about both of our recent acquisitions and will continue to seek companies that will increase shareholder value.”

About Genesis Electronics Group, Inc.

Genesis Electronics Group, Inc. is a holding company which makes acquisitions, investments, and enters into strategic business partnerships. The Company works with organizations that are looking for capital, management assistance, or help in reaching their target markets to realize their true potential. In May 2008, Genesis completed a merger with Genesis Electronics, Inc., a company that is engaged in the development of solar and alternative energy applications for consumer devices such as mobile phones device. www.genesiselctroincsgroup.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words such as “anticipate,” “believe,” “expect,” “future,” “may,” “will,” “would,” “should,” “plan,” “projected,” “intend,” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Genesis to be materially different from those expressed or implied by such forward-looking statements. Genesis’s future operating results are dependent upon many factors, including but not limited to the Company’s ability to: (i) obtain sufficient capital or a strategic business arrangement to fund its expansion plans; (ii) build the management infrastructure necessary to support the growth of its business; (iii) competitive factors and developments beyond the Company’s control; and (iv) other risk factors.

CONTACT: Ray Purdon
         Tel: (732) 936-8692
         Email: info@gennesiselectronicsgroup.com

(PNTV) Approval of Conditional Use Permits for Medical Marijuana Cultivation and Production

LAS VEGAS, NV, United States, via ETELIGIS INC., 10/17/2014 – – Players Network (OTCQB: PNTV), a Digital Television, Technology and New Media company that develops, owns, and operates Branded Lifestyle Channel Destinations announces today that the City of North Las Vegas approved two Condition Use Permits for Medical Marijuana Cultivation and Production Facilities. Green Leaf Farms Holdings of which 80% is owned by Players Network (Company and/or PNTV) is the contract purchaser of 3.2 acres of land on Apex Great Basin Way in North Las Vegas, Nevada. The Conditional Use Permits are for a Cultivation Facility for Medical Marijuana and a Production Facility for Edible Medical Marijuana and Marijuana-Infused Products on this property.

Mark Bradley CEO of Players Network states, This is an extremely important approval for the Company. As stated in previous press releases Green Leaf Farms Holdings (GLFH) applied for three permits, two within North Las Vegas and a dispensary permit in Las Vegas which is still in review. Capital has already been raised in GLFH for these applications at a $10 million valuation. This valuation was prior to these approvals being granted which increases the GLFH valuation. It is important to note that GLFH could not begin this application process without already having a first class operational team and financial resources in place. The next step is Nevada State review and approval. The State is expected to make their determinations by November 18, 2014. Based upon the strength or our team and financial resources we are confident that our application meets all State requirements. I also granted WeedTv an interview which can be read at http://weedtv.com/category/finance that provides additional information. I encourage you to read the interview at Weedtv.com.

Mr. Bradley continues, PNTV is a digital media company operating branded channel destinations where WeedTv is one of our channel destination. We are not getting out of the media business; GLFH will provide a strong recurring revenue stream to the Company as well as a rich source of program content for our Weedtv channel. This sector will be one of the most dynamic and high growth industries for the next 5 to 10 years. This is a professional, regulated and licensed industry focused on helping people with real needs and providing sustainable raw materials. PNTV remains focused on achieving our operational goals bringing shareholder value and growth opportunities.

About Players Network:

Players Network is a Television and Digital New Media Company that uses its proprietary Enterprise Web Platform to develop numerous Branded Digital Lifestyle Networks for itself and its partners in a wide range of lifestyle categories. Players Networks current original channels, Players Network, Vegas on Demand, Real Vegas TV, focus on Las Vegas and Gaming Lifestyles and the newest Channel is WeedTV. They are distributed over PNTVs owned and operated VOD Channels on TV in over 23,000,000 homes over Comcast, its Broadband Network and Mobile Platforms, on Hulu, Google, YouTube, Blinkx and Yahoo Video, on DVD, and through worldwide television syndication. For more information please visit www.playersnetwork.com

About WeedTV:

WeedTv is the go to source for informational, entertainment, products and services for people who relate to the marijuana lifestyle and social community. Weed TV provides a wide variety of editorial content, videos and entertainment including lead stories, political news, business news on the industry, financial analysis from industry experts, growing tips, cooking tips, a Weed101 section, medical uses, lifestyle features, entertainment specials and merchandise shopping cart offering products and services.

Statement under the Private Securities Litigation Reform Act:

With the exception of the historical information contained in this Release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to: the ability of the Company to increase revenues in the future due to the developing and unpredictable markets for its products, the ability to achieve a positive cash flow, the ability to obtain orders for or install its products, the ability to obtain new customers and the ability to continue to commercialize its products, which could cause actual results or revenues to differ materially from those contemplated by these statements.

CONTACT:

Media inquiries contact

Lisa Mayo-DeRiso

702.576.2659

For Investor inquiries

Parker Mitchell

702-575-9157

(NUTT) Michael P. Ressner Joins Advisory Board

(NETE) Files $50 Million Universal Shelf Registration Statement

Registration Statement is Intended to Provide the Company with Increased Financial Flexibility

MIAMI, Oct. 17, 2014  — Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a technology-driven group specializing in mobile payments and value-added transactional services in emerging countries and in the United States, has filed a universal shelf registration statement on Form S-3 with the Securities and Exchange Commission (“SEC”). The registration statement is intended to provide the Company with increased financial flexibility to execute on its business strategy and invest in opportunities in mobile payments and value-added transactional services. Although the registration statement relating to these securities has been filed with SEC, it has not yet become effective.

If and when the registration statement is declared effective by the SEC, the Company will be able to offer and sell, from time to time, up to $50 million of the Company’s common stock, preferred stock, warrants, units and/or subscription rights in one or more offerings and in any combination, and certain selling securityholders will be able to offer and sell, from time to time, up to 15.4 million shares of Company’s common stock, each on the terms which will be described in prospectus supplements filed with the SEC, as applicable.

A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Any offering of the securities covered under the shelf registration statement will be made solely by means of a prospectus and an accompanying prospectus supplement relating to that offer.

Net Element’s shelf registration statement on Form S-3, which was filed with the SEC October 16, 2014, may be obtained from the SEC’s Internet website at http://www.sec.gov.

About Net Element (NASDAQ: NETE)   

Net Element (NASDAQ: NETE) is a global technology-driven group specializing in mobile payments and value-added transactional services. The Company owns and operates a global mobile payments and transaction processing provider, TOT Group. TOT Group companies include Unified Payments, recognized by Inc. Magazine as the #1 Fastest Growing Private Company in America in 2012; Aptito, a next generation cloud-based point of sale payments platform; and TOT Money, which has a leading position in Russia and has been ranked as the #1 SMS content provider by Beeline, Russia’s second largest telecommunications operator. Together with its subsidiaries, Net Element enables ecommerce and adds value to mobile commerce environments. Its global development centers and high-level business relationships in the United States, Russia and Commonwealth of Independent States strategically position the Company for continued growth. More information is available at www.netelement.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements. Words such as “continue,” “will,” “may,” “could,” “should,” “expect,” “expected,” “plans,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, whether Net Element or its business continues to grow and whether any financing secured by Net Element will be adequate to meet the Company’s objectives.  All forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in the forward-looking statements, many of which are generally outside the control of Net Element and are difficult to predict. Examples of such risks and uncertainties include, but are not limited to: (i) Net Element ‘s ability (or inability) to obtain additional financing in sufficient amounts or on acceptable terms when needed; (ii) Net Element ‘s ability to maintain existing, and secure additional, contracts with users of its payment processing services; (iii) Net Element ‘s ability to successfully expand in existing markets and enter new markets; (iv) Net Element ‘s ability to successfully manage and integrate any acquisitions of businesses, solutions or technologies; (v) unanticipated operating costs, transaction costs and actual or contingent liabilities; (vi) the ability to attract and retain qualified employees and key personnel; (vii) adverse effects of increased competition on Net Element ‘s business; (viii) changes in government licensing and regulation that may adversely affect Net Element ‘s business; (ix) the risk that changes in consumer behavior could adversely affect Net Element ‘s business; (x) Net Element ‘s ability to protect its intellectual property; (xi) local, industry and general business and economic conditions; (xii) adverse effects of potentially deteriorating U.S.-Russia relations, including, without limitation, over a conflict related to Ukraine, including a risk of U.S. government sanctions or other legal restrictions on U.S. businesses doing business in Russia. Additional factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements can be found in the most recent annual report on Form 10-K and the subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K filed by Net Element with the Securities and Exchange Commission. Net Element anticipates that subsequent events and developments may cause its plans, intentions and expectations to change. Net Element assumes no obligation, and it specifically disclaims any intention or obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by law.

(ILST) Provides Van Deemen Progress

WILTON, CT / October 16, 2014 / International Star, Inc. (OTC Pink: ILST), provides Van Demeen project update.

International Star (the “Company”) is pleased to provide the progress made with its Plan of Operations. As previously announced, the Company delivered its Preliminary Plan of Operation to the Bureau of Land Management (“BLM”). The BLM has asked the Company to expand the scope of its Preliminary Plan of Operation to a Plan of Operations.

The Plan of Operations covers numerous subjects in 18 separate sections. Sections include but are not limited to, Descriptions of Plan Operations, Water Management, Rock Characterization and Handling, Dust Abatement, Reclamation and Monitoring. Each of these sections are technical and require a thorough review of each process.

As sections are completed, the Company is providing the data to the BLM for review and feedback. By example, the following is a summary of Rock Characterization and Handling requirements,

Rock characterization and handling plans describe how ILST will manage rock that may require special handling, e.g., due to its potential to generate acid or deleterious leachate, is to be managed.62 The plans must include the analytical protocols and criteria that will be used to identify potential acidic or reactive rock. The plan must include how such material is to be (1) identified by testing prior to and during mining, (2) selectively handled, (3) processed or treated, and (4) reclaimed. These plans are integral to the “source control” of acid-forming, toxic, or other deleterious material as described in the performance standards (Section 5.3.11.1, Source Control Requirements).

To meet these requirements, the Company has submitted rock samples to an accredited lab for testing.

All this work is primarily being done internally which has allowed the Company to make substantial progress without dilution.

Michael Shea, CEO stated, “I realize that this process is taking longer than planned, however, we are making substantial progress and look forward to completing the Plan of Operations as quickly as possible. Management remains very optimistic regarding the Van Deemen project and looked forward to keeping the investment community apprised of our progress”.

ABOUT INTERNATIONAL STAR

International Star is a junior mining Company with claims in Arizona. Its primary focus is to bring the Van Demeen gold project into production. The primary goal is to generate cash flow to sustain and grow profitability.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words “anticipate,” “believe,” “estimate,” “may,” “intend,” “expect” and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

CONTACT:

Michael Shea
International Star, Inc.
Phone: (203) 210-5614
Email: Mshea@ilstholdings.com

www.ilstholdings.com

(NBRI) Issues Shareholder Update

(WTCG) Subsidiary, AdMedia Group, Inc., Plans Expansion Into San Diego County

(ETAH) Developing a Multi Channel Needle-Free Injection Device for Mass Vaccination

PHOENIX and VANCOUVER, B.C., Oct. 16, 2014 — Eternity Healthcare Inc. (OTC:ETAH), a medical device and diagnostic company with advanced technologies in Needle-Free Injection systems, announced today that it is developing a multi channel Needle-Free Injection device system for delivery of vaccines intramuscularly.

Currently vaccines are administered with a single use needle; these needles are not only painful for the patient but carry the risk of transmitting diseases such as Ebola and HIV. With this new technology, Health Care workers can vaccinate up to twelve patients with a single multi channel Needle-Free cartridge. With this new technology Health Care workers not only eliminate cross contamination of diseases, but cut in half the amount of time needed to administer vaccines; thus being able to vaccinate more people in the same amount of time.

Dr. Salari, President & CEO of Eternity Healthcare Inc., stated: “Eternity Healthcare currently has on the market the Comfort-in™ Needle-Free Injection System, this device is designed to deliver drugs and medications under the skin.” He went on to state: “Eternity Healthcare is currently developing an enhanced version of this Needle-Free Injection device. This new device will be suitable for multiple injections thus will be far more suitable for mass population vaccination.” Dr. Salari further elaborated, “With the recent FDA approval to use a Needle-Free Injection device to administration vaccines, such as Influenza, it opens the door for a large number of injectable vaccines, to be injected without the use of needles.”

About Eternity Healthcare

Eternity Healthcare or the “Company” (OTC:ETAH) is a healthcare company with technologies in medical devices and diagnostics. Our most advanced product is a needle-free injection system known as Comfort-in^TM. Our products are sold to healthcare professionals, for use in physicians’ offices, pharmacies, and to consumers directly. More information on Eternity Healthcare, visit the Company’s website: www.eternityhealthcare.com

Social Networks:                                           

Twitter.com/EternityHealth

Facebook.com/EternityHealthcare

Safe Harbor Statement

This release includes forward-looking statements. These forward-looking statements generally can be identified by phrases such as ETAH or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, statements herein that describe the Company’s business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.

CONTACT: Company Contact:
         Lena Kuang
         Sale Manager
         (855) 324-1110
         info@eternityhealthcare.com

(WWIO) On a Roll Announces Another Deal

Four-Issue Series of “Wildfire” comic series to be released as a Trade Paperback with Volume 2 to be released 2015

WEST HOLLYWOOD, CA / October 16, 2014 / WOWIO, Inc. (OTCBB: WWIO), a digital media technology company with a patented process for inserting ads into eBooks, a mobile eBook distribution platform, and a proprietary mobile ad network, is pleased to announce that the company and its publishing partner, Top Cow Productions, will be releasing the Volume 1 trade paperback of the four-issue series of “Wildfire,” the landmark series that tackled the topical issue of genetically-modified organisms (GMOs). Following the recently announced publishing deal with rock historian Marc Platt, WOWIO’s new arrangement with Top Cow Productions extends the project for a second four-issue series to be released both in print and digital formats in 2015.

“Wildfire Volume 1” will be available in time for this year’s holiday season. The series was written by Top Cow’s President Matt Hawkins, who has also adapted the series as a feature film project.

“The reviews for the first series of “Wildfire” have been so positive and the sales have been really impressive for an independent release,” said Brian Altounian, WOWIO’s CEO. “Matt has a way of delving deeply into topical and controversial storylines and presenting both sides with brilliance and wit, and the fans seem to have really embraced his story, combined with the beauty that artist Linda Sejic has painted to bring “Wildfire” to life. We are quite excited as WOWIO is now accumulating deals with recognizable names. Our production team has been quite busy and as we now start to see the positive effects of these efforts, our shareholders will be happy as we expect to see an ROI soon.” The company developed additional media content around the comic series for distribution across its digital media outlets such as its 4-part interview with Matt Hawkins on its Pop Galaxy channel. WOWIO has released the series on its proprietary eBook distribution platform at wowioapp.com and on Comixology and other digital platforms as well. “Wildfire” represents the first WOWIO-owned property to be released on the company’s recently announced mobile app available through Google Play.

“We got such great feedback on this project,” says Wildfire creator/writer and Top Cow President Matt Hawkins. “In my own exploration of the discussion about GMOs, I was amazed by the change in my own position on the topic and I am looking forward to further development with the second series and the feature film adaptation.”

In addition to its library of creative content, WOWIO holds a proprietary patent that allows for the insertion of advertising into eBooks, providing the digital publishing distribution channel as a viable alternative to that of other content distribution outlets. For further information and updates, follow WOWIO on social media and at www.studiowdigital.com.

About WOWIO, Inc.

WOWIO, Inc., (OTCBB:WWIO) is a technology development company with a patented process and a proprietary mobile ad-delivery platform that will disrupt the eBook distribution landscape by exploiting a previously untapped marketplace: AD-SUPPORTED eBOOKS! Our exclusive ownership of an issued patent that governs this opportunity allows us to expand our reach as a digital media company far beyond producing and distributing content across multiple platforms. WOWIO has built and acquired a number of digital media technologies, platforms and distribution outlets and is focusing its efforts on opportunities to create and monetize ancillary content product lines beyond eBooks and other forms of digital media. To learn more: www.studiowdigital.com

Corporate Contact:

Jacob Morris
WOWIO, INC.
(310) 807-8122
jmorris@wowio.com

Investor Relations:

Juan Ferreira
Newport Coast Securities
(407) 399-8190
jferreira@ncsecurities.com

About Top Cow Productions

Top Cow Productions, Inc. (http://www.topcow.com/), a Los Angeles-based entertainment company, was founded in December of 1992 by artist Marc Silvestri, who also co-founded Image Comics earlier that same year. Top Cow currently publishes its line of comic books in 21 languages in over 55 different countries. The company has launched 20 franchises (18 original and two licensed) in the industry’s Top 10, seven at #1. Virtually all of Top Cow’s other properties are in development as feature films, live-action television, animation or video games. The 2008 film WANTED, starring Angelina Jolie, the TNT TV series Witchblade, the Japanese anime Witchblade and the two The Darkness video games for XBOX 360 and PS3 are all based on Top Cow properties. The company has also successfully licensed and merchandised its franchises into toys, statues, clothing, lithographs, puppets, posters, magnets, shot glasses, lighters, lunch pails, wall scrolls, mouse pads, die-cast cars, calendars, Christmas ornaments, Halloween masks, trading cards, standees, video games, and roleplaying games.

Corporate contact:
Matt Hawkins
matt@topcow.com

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

(ALGA) ‘Farmers Wanted’ Campaign Highlighted In New Article By Hemp Industry Herald

Dallas, TX / October 16, 2014 / Algae International Group, Inc. (OTC: ALGA), through its operating subsidiary American Seed & Oil Company, Inc., announced today a new article released by Doug Fine, the author of ‘Hemp Bound:’

Hemp is on its Way to Your Car Battery and Many Things You Haven’t Yet Imagined

Mr. Fine’s article provides a comprehensive and entertaining update on the U.S. hemp industry through the 2014-growing season. He also envisions the coming future of hemp in the digital age reporting on current uses of hemp most people would never imagine, to include nanotechnology applications using hemp in the construction of supercapacitors to replace current battery technology. Fine’s article goes on to highlight specific projects in the only three States in the U.S. where hemp was grown in 2015: Colorado; Kentucky, and Vermont. Fine highlights the exceptional economic potential of hemp grown in Vermont and enthusiastically applauds American Seed & Oil Company’s campaign to recruit hemp farmers.

American Seed & Oil Company is recognized as the largest legal hemp grower in the State of Vermont.

Share Structure:

As of October 2014, the Company has approximately 31 million common shares issued and outstanding.

About Algae International Group, Inc.

Algae International Group, Inc. (OTC: ALGA), through its operating subsidiary American Seed & Oil Company, Inc., is in the business of hemp production in Vermont to supply seed to the expanding hemp farming market, hemp based consumer products market, and hemp based construction material market. The Company is also piloting a number of other cannabis related products. For more information please visit www.americanseedandoil.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company’s actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.

CONTACT:

Mike Murphree
Phone: 972.528.0162
Email: mike.murphree@americanseedandoil.com

(MECK) Inside Bitcoins Conference & KINTEX Announce Cryptocurrency Trade Show in South Korea

NEW YORK, Oct. 15, 2014  — MecklerMedia (OTCQX: MECK) announced that the Inside Bitcoins Conference and Expo taking place in Seoul on December 12-13 will be South Korea’s first major cryptocurrency event.

Inside Bitcoins Seoul will be co-produced by MecklerMedia and the Korea International Exhibition Center (KINTEX).

The event will feature a lineup of both local and international experts, including Jacob Hansen, CEO & Co-Founder, CrowdCurity; Prof. Hoh Peter In, Ph.D. Professor, Department of Computer Science, College of Informatics, Korea University; Zennon Kapron, Managing Director, Kapronasia; Mr. Casey Ilsun Kim, CEO, InfraBasic and Adjunct Professor, Hanyang University Business School; Tony Lyu, CEO, Korbit; and more.

Early bird prices will expire on October 31, so attendees are encouraged to register before then for the best rate. For complete information on Inside Bitcoins Conference and Expo, visit insidebitcoins.com.

If your company is interested in sponsoring or exhibiting, contact us at eventsales@mecklermedia.com.

About MecklerMedia
MecklerMedia (OTCQX: MECK) is the producer of conferences including Inside 3D Printing, Inside Bitcoins, and AllFacebook Marketing Conference. MecklerMedia produces over 25 conferences annually. The MecklerMedia news sites and newsletters, including Inside Bitcoins News, 3D Printing Industry, and Allfacebook.de provide up-to-date coverage on emerging industries to help drive business forward.

(NVIV) Announces First Subject Enrolled in Pilot Spinal Cord Injury Trial

InVivo Therapeutics Holdings Corp. (NVIV) today announced that the first subject has been enrolled in the pilot study of its Neuro-Spinal Scaffold for the treatment of complete traumatic spinal cord injury (SCI) at the Barrow Neurological Institute at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. The objective of the pilot study is to evaluate the safety and feasibility of the Neuro-Spinal Scaffold as well as to gather preliminary evidence of effectiveness.

Dr. Nicholas Theodore, Chief of Spinal Surgery, Barrow Neurosurgical Institute and Medical Director of the Neurological Trauma Program, is a Principal Investigator in this study and implanted the first-ever Neuro-Spinal Scaffold into an acute spinal cord injury patient. “I am excited about my participation in this important clinical trial,” Dr. Theodore said. “The surgery and Neuro-Spinal Scaffold implantation went smoothly and the patient is doing well at this time. I look forward to continuing to help evaluate this approach in patients with these devastating injuries.”

Mark Perrin, InVivo’s CEO, said: “This is a major milestone not only for the company, but also for the field of traumatic SCI. InVivo is striving to provide benefit to the SCI patient population with such a huge unmet medical need, and this clinical trial is the first step. We look forward to communicating our progress and moving forward. InVivo will be making announcements after each site has joined the study, after each subject is enrolled, and once enrollment is re-opened for subsequent patients. We consider patient privacy of the utmost importance and will thus communicate any interim information according to industry standards. With the exception of dramatically positive or negative results, we will look to communicate progress at appropriate medical or scientific forums.”

As previously stated and per FDA requirements, the company will follow the first enrolled subject for three months before re-opening enrollment.

For more information, please visit our ClinicalTrials.gov registration site:
http://clinicaltrials.gov/ct2/show/study/NCT02138110

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a pioneering biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, MD, who then was at Boston Children’s Hospital and now is affiliated with Massachusetts General Hospital. In 2011 the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect” and similar expressions, and include statements regarding the Company’s expectations with respect to the safety, feasibility, and clinical effectiveness of its scaffold device, the enrollment of subsequent patients in the scaffold pilot study following the reopening of enrollment, and the potential market for the treatment of spinal cord injuries. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to successfully open additional clinical sites for enrollment; the timing of the Institutional Review Board process; the Company’s ability to obtain FDA approval to commercialize its products; the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013, as amended, and its other filings with the SEC, including the Company’s Form 10-Qs and current reports on Form 8-K. The Company does not undertake to update these forward-looking statements.

(OEDV) Announces New Well Rates of 1306 BOE

Osage Exploration and Development, Inc. (OTCBB:OEDV), an independent exploration and production company focused on the Horizontal Mississippian and Woodford plays in Oklahoma, announced today preliminary production results from the McNally 1-29MH and the McNally 1-20WH, located in Logan County, Oklahoma.

The McNally 1-29MH, a horizontal Mississippian well in Section 29-17N-2W, has reached a one-day production rate of 695 BOE. The product mix is 84% crude oil and 16% natural gas. Osage has approximately a 58% Working Interest in the well.

The McNally 1-20WH, a horizontal Woodford well in Section 20-17N-2W, has reached a one-day production rate of 611 BOE. The product mix is also 84% crude oil and 16% natural gas. Osage has approximately a 76% Working Interest in the well.

Management Comments

“Since Osage took operational control in Logan County we have reiterated that the second half of 2014 would be a time of great change for our shareholders. We ended the first half of this year producing about 425 barrels of oil equivalent net to Osage from 43 non-operated wells. With only four Osage-operated wells added to that total, we have more than tripled our daily production to 1,392 barrels of oil equivalent, far in excess of the target year-end exit rate that we promised publicly just 45 days ago,” stated Kim Bradford, Chairman and CEO.

“Our Mississippian well, while still early in its production life, is well ahead of the type curve and promises to be an exceptional well with early payback. Our Woodford well is without a doubt the best Woodford well drilled in southern Logan County, and better by far than any Woodford well drilled by any offset operator outside of Devon Energy. The impact of this is enormous to the Osage shareholder because it proves our assertion that we can drill multiple Mississippian wells and multiple Woodford wells in every section that we operate,” stated Jack Zedlitz, VP Corporate Development.

“The quality of our rock has never been seriously questioned, but it took the right operational team with the right philosophy to bring everything to fruition,” stated Greg Franklin, Osage’s Vice President of Exploration and Senior Geologist.

“Looking beyond these exceptional results, we already have two more Mississippian wells drilled which we will frac later this month, and our next two drilling pads under construction to move our rig to sequentially. We have built a team of exceptional individuals to execute this plan and our results speak for themselves. Even with the high level of production that we are seeing, our primary focus is on cutting drilling and completion costs, which is crucial in this volatile commodity price environment. While these are still the early days of our development program, we have put exclamation points on our geology, our team, and our ability to deliver results, all to the benefit of our shareholders,” concluded Kim Bradford.

About Osage Exploration and Development, Inc.

Based in San Diego, California, with production offices in Oklahoma City, Oklahoma, Osage Exploration and Development, Inc. is an independent exploration and production company with interests in oil and gas wells and prospects in the U.S. http://www.osageexploration.com

Safe Harbor Statement

The information in this release includes certain forward-looking statements as defined by the Securities and Exchange Commission that are based on assumptions that in the future may prove not to have been accurate. Those statements and Osage Exploration and Development, Inc. are subject to a number of risks, including production variances from expectations, volatility of product prices, inability to raise sufficient capital to fund its operations, environmental risks, competition, government regulation, and the ability of the Company to execute its business strategy, among others.

(LOTE) Expands Distribution with Harvey Nichols in Dubai for Autumn/Winter ’14

NEW YORK, Oct. 15, 2014  — Lot78, Inc. is pleased to announce that the Company has secured retail distribution with Harvey Nichols in Dubai.

Harvey Nichols: Harvey Nichols has stores in London, Leeds, Edinburgh, Birmingham, Manchester and Bristol. It also has a store in Al-Faysaliyah Tower in Riyadh, Saudi Arabia, a store at Dundrum Town Centre, Dublin in Ireland and one in Central, Hong Kong. It opened a store in Istanbul’s Kanyon Shopping Mall on 13 October 2006. In February 2006, it opened a store in Dubai, designed by architecture firm Callison in the Mall of the Emirates. The Dubai store is operated by Al Tayer Insignia, (Al Tayer group LLC) the luxury retail arm of Al Tayer Group.

“We are excited to increase our mainstream profile and expand our brand reach in Dubai with our women’s collection which will add to our existing men’s business,” says Ollie Amhurst, President and CEO of Lot78, Inc.

About Lot78, Inc.

Lot78, Inc. is a trend-setting leader in the design, marketing, distribution and sale of urban apparel – retailing under the brand name “Lot78” in six continents, including: North America, Europe, Asia, Australia, Africa and South America. Lot78 has been featured in US Weekly, Elle Magazine, Financial Times, Harrods Magazine, The London Evening Standard, and Grazia Magazine as an emerging global brand. Lot78, Inc. is quoted on the OTC Bulletin Board in the United States of America under the symbol LOTE.OB. For more information, please visit www.lot78.com.

Forward-Looking Statements

This news release contains “forward-looking statements,” as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, Lot78’s products to gain market acceptance, and the difficulties faced by an early stage retail fashion company in the competitive retail fashion industry. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the Company’s recent current reports on Form 8-K, our annual report on Form 10-K, our quarterly reports on Form 10-Q, and other periodic and current reports filed from time to time with the Securities and Exchange Commission.

(CTRV) Closes $9.0 Million Financing to Advance Lead Shingles Candidate

Proceeds to Fund Phase 2b Study of FV-100 Fast-Acting Oral Antiviral

EDISON, N.J., Oct. 15, 2014  — ContraVir Pharmaceuticals, Inc. (OTCBB: CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it has closed a private placement of shares of Series A Convertible Preferred Stock to a non-U.S. investor with gross proceeds of $9.0 million.  The Preferred Stock is convertible at any time into shares of common stock at a conversion price of $0.48 per share.  The investor has agreed to lock-up the shares of Preferred Stock and the underlying common stock until April 14, 2016.

ContraVir intends to use the net proceeds of the transaction to fund the initiation of a Phase 2b clinical study for the Company’s lead clinical asset, FV-100, a fast-acting, once-daily oral antiviral agent being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus. FV-100 also has the potential to further reduce the incidence, severity, and duration of shingles-associated pain and prevent post-herpetic neuralgia (PHN).

“This $9.0 million financing is the first step in a corporate and clinical strategy to accelerate the growth of ContraVir and seize upon the significant potential of FV-100,” stated James Sapirstein, chief executive officer of ContraVir Pharmaceuticals. “Not only are we now capitalized to initiate the Phase 2b clinical trial of FV-100 in shingles, but we are also well positioned to target additional opportunities to add to our pipeline and build ContraVir as a multifaceted antiviral company.”

The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. For additional information, please refer to ContraVir’s current report on Form 8-K to be filed with the Securities and Exchange Commission with respect to the private placement.

About ContraVir Pharmaceuticals

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies. ContraVir’s lead candidate, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus (VZV). Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, famcyclovir, and valacyclovir, the FDA approved drug for treating shingles. Moreover, FV-100 has been shown to have a more rapid onset of antiviral activity in preclinical models, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels and with a better dosing regimen. Phase 1 trials of FV-100 in volunteers were successfully completed, as well as a Phase 2a clinical trial in shingles patients. ContraVir plans to conduct a Phase 2b trial in patients with shingles to further explore FV-100’s potential to treat the long-lasting nerve pain typically associated with shingles. ContraVir was formed in May 2013 by Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) and spun off as an independent public company in January 2014. For more information, please visit www.contravir.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on ContraVir’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any drug candidates under development, there are significant risks in the development, regulatory approval, and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful, or that any product will receive regulatory approval for any indication or prove to be commercially successful. ContraVir does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in ContraVir’s Form 10-K for the fiscal year ended June 30, 2014, and other periodic reports filed with the Securities and Exchange Commission.

For further information, please contact:

Tiberend Strategic Advisors, Inc.

Joshua Drumm, Ph.D. (investors)
jdrumm@tiberend.com; (212) 375-2664

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686

(CALI) Global Lock Notice Suspended by Depository Trust Company

(WDRP) Signs Crop Share Agreement with California Dispensary

SANTA MONICA, CA, United States, via ETELIGIS INC., 10/14/2014 – – WanderPort Corp. (OTC Pink: WDRP) (PINKSHEETS: WDRP), today announced that it has signed a Crop Share Agreement with a Southern California dispensary.

The crop share agreement as provided under California Proposition 215 and Senate Bill 420, allows for the cooperative cultivation, possession, transportation and use of marijuana for medical purposes within the state of California.

“Crop sharing is a great way for Wanderport to participate in the fast growing medical marijuana industry, said Eric Brown, Chief Executive Officer. This is one of many investments we will make to build a solid and diversified portfolio of bona fide cannabis related assets added Brown.

About Wanderport Corp.

Wanderport Corporation specializes in licensing, distribution and obtaining proprietary rights to various unique technology while continuing to be an acquisition minded company targeting various licenses, technologies and/or companies in key emerging growth industries.

Forward-Looking Statements:

Statements made herein, other than historical data, constitute forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those stated or implied by such forward-looking statements. The potential risks and uncertainties include, among others, potential volatility in the company’s stock price, increased competition, customer acceptance of new products and services to be offered by the company, and uncertainty of future revenue and profitability and fluctuations in its quarterly operating efforts.Forward-looking statements are projections of events, revenues, income, future economics, research, development, reformulation, product performance or management’s plans and objectives for future operations.In some cases you can identify forward-looking statements by the use of terminology such as “may”, “should”, “anticipates”, “believes”, “expects”, “intends”, “forecasts”, “plans”, “future”, “strategy”, or words of similar meaning.While these forward-looking statements and any assumptions upon which they are based are made in good faith and reflect current judgment regarding the direction of the business operations of Wanderport Corporation, actual results will almost always vary, sometimes materially, from any estimates, predictions, projections, assumptions or other future performance suggested in this press release.These statements are predictions and involve known and unknown risks, uncertainties and other factors, including the risk that Wanderport Corporation cannot execute its business plan for lack of capital or other resources, distribution, licensing/acquisition opportunities or internal partnering issues or restructuring/resignation which may modify existing licensing agreement, arrangements and/or contractual obligations, as well as the risks described in the periodic disclosure documents filed on OTCMarkets.com by Wanderport Corporation. Any of these risks could cause Wanderport Corporation or its industry’s actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by the forward-looking statements in this press release. Except as required by applicable law, including the securities laws of the United States, Wanderport Corporation does not intend to update any of the forward-looking statements to conform these statements to actual results.

CONTACT:

Wanderport Corporation

www.wanderportcorp.com

Investor Relations:

info@wanderportcorp.com

(310) 526-8720

(VSYM) Announces Letter of Intent to Merge With Potomac River Group

(STLK) Issues Investor Update

COLORADO SPRINGS, Colo., Oct. 14, 2014  — STL Marketing Group, Inc. (OTC: STLK) is issuing a brief investor update on its progress since its Shareholder Conference Call this past August. The Company has been working on various goals since its last update and has made progress on establishing new dealers for its new PhoneSuite Solutions business, as well as, its new Letter of Interest from the Export-Import Bank (Ex-Im Bank). This update is to report on key items discussed at that meeting.

“The last 60 days has seen steady work behind the scenes with regard to the PhoneSuite Solutions development. Some of this development has been to our internal office infrastructure, for example we have implemented SIP trunking and our Voiceware by PhoneSuite^® VoIP PBX has been installed with a fully functional IVR. Our web page redeployment is close at hand and will more accurately reflect the corporate structure with separate sites for PhoneSuite Solutions and Energía Renovable Versant. Along with our existing IR efforts, we have also begun to implement a software application to help us better manage our Social Media and we hope to have ongoing updates through those channels on a consistent basis as a result. These developments are designed to help us handle the expected sales for the PhoneSuite brand of products, as well as help to keep our shareholders updated.

More importantly, from a revenue perspective, we have begun to establish the necessary dealers in various parts of the world, the first being Exodus for the UAE and Indian markets. We are working with dealers in other areas (e.g. Australia, Malta, Saipan, etc.) and expect to have more announcements on new dealers as we get dealer contracts in place. The dealer process does require a dealer agreement; this makes the process slow at the onset, but is more meaningful than a non-contracted “appointment” to distribute the line. Additionally, our outreach effort for new SMB business here in the USA, through Response Logic, began a little over a week ago, and is yielding good leads for the product.  We are positive on the progress made thus far, and hope to report more positive progress in the months to follow.

As to energy, we are working on getting our status as per our last shareholder call. We have confirmed the delay on new projects as previously reported from various sources. Unfortunately, this area continues to be a slow process. We do hope to have a project status update before year-end. We have been working with the Export-Import Bank for a new Letter of Interest, as our last letter has expired. Ex-Im has undergone some reorganization and changed their internal process which have caused delays, but we feel confident we should get that important letter of support soon,” said Jose P. Quiros, CEO of STL Marketing Group, Inc.

About STL Marketing Group, Inc./ Versant Corporation
STL Marketing Group, Inc. is a Colorado based company that sells, distributes and markets the PhoneSuite brand of VoIP telecommunications equipment (through its wholly owned subsidiary PhoneSuite Solutions, Inc.,), as well as, working on the development of renewable energy opportunities (through its wholly owned subsidiary Energia Renovable Versant SRL).  For more information on STLK, please visit our web site at www.STLmarketingGroup.com or www.v3rsant.com .

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plan, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

(NNLX) Being Configured For Rapid Ebola Virus Detection

NanoLogix Inc. (NNLX), an innovative biotechnology company in Northeastern Ohio announces that it is configuring its N-Assay Rapid diagnostic kits for both Ebola Virus and Enterovirus detection and identification. NanoLogix CEO Bret Barnhizer stated, “The Company has been aware of the virus detection capabilities of the technology since the N-Assay development. Viruses viewed as public health concerns prior to Ebola and Enterovirus were Influenza, the common cold, and HIV, none of which have an immediate or near-immediate threat of mortality. Until recently, NanoLogix has been focused solely on the use of their N-Assay kit for bacteria detection and identification. Now, with the recent outbreaks of both Ebola and Enterovirus there is an immediate need for configuration of the N-Assay for viruses. NanoLogix facilities are not designed for work on viruses, for this specific project we are seeking a corporate partner with the facilities necessary to bring the new N-Assay (V) to the market as quickly as possible. We consider this a matter of national security and an emergency priority. We are in discussions with potential partners, positioned with strong ties to the US government, who understand the serious threat these viruses represent.”

The NanoLogix N-Assay (V) ELISA is one of six technologies that may be used for virus detection and identification, the N-Assay (V) has unique qualities that contribute to both its rapid detection capability and long term durability that should be attractive to personnel in both developed and remote locations interested in a screening test that may provide results for Ebola or other viral threats in 30 minutes to a few hours.

Supporting information on the N-Assay (B), used for bacterial detection and identification and evidence of the capabilities of one version of the technology can be found by following this link:

http://nanologix.com/resources/index.html

Sebastian Faro, MD, PhD, is considered one of the top experts in the world on Infectious diseases of women’s reproductive systems. Dr. Faro made the following comments: “N-Assay ELISA technology has been applied to the rapid identification of specific bacteria, e.g. Streptococcus agalactiae (GBS), Neisseria gonorrhoeae, & Enterococcus faecalis. This technology has been used to rapidly identify strains that are resistant to specific antibiotics. This technology significantly reduces the time from specimen submission to identifying these bacteria and resistance to specific antibiotics. This N-Assay ELISA technology can be applied to identifying viruses and is inexpensive. This technology does not require expensive equipment which makes this technology ideal for a variety of laboratory environments.”

His presentation on the N-Assay is in the following YouTube links:

https://www.youtube.com/watch?v=TCG_ihwwrBQ

https://www.youtube.com/watch?v=kshzguaO7uk

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical, National Defense, and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing.

Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology and bioremediation, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity.

For more information visit: http://www.nanologix.com

This press release contains statements, which may constitute “forward- looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

(CNET) Launches Zero Down Payment Loans in Cooperation With Haodai and Yooli

BEIJING, Oct. 14, 2014  — ChinaNet Online Holdings, Inc. (Nasdaq:CNET) (“ChinaNet” or the “Company”), a leading B2B (business to business) Internet technology company providing online-to-offline (O2O) sales channel expansion services for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking services for entrepreneurs in the People’s Republic of China, today announced the launch of Zero Down Payment Loans. The product, targeted toward entrepreneurs, is being offered with Chinese financial services companies Haodai, which offers a credit product search engine, and Yooli China’s leading crowdfunding services Web site.

ChinaNet is taking a leading role in the Zero Down Payment Loans offering. The product integrates banks, P2P, and security companies with reputable enterprise franchising resources. The service will significantly lower the hurdles that many entrepreneurs face and help them to realize their business objectives.

Neither Haodai nor Yooli provide loans, but focus on helping individuals and small-to-medium sized businesses screen loan opportunities in the financial markets. The new Zero Down Payment Loans product will facilitate communications between potential borrowers and lenders. ChinaNet customers will benefit significantly as many are in need of capital for expansion hundreds of thousands of entrepreneurs who need capital will benefit from ChinaNet’s cooperation with other financial service providers, and will be able to achieve their business goals more quickly.

ChinaNet COO George Chu says, “In 2014, the number of mobile Internet users in China exceeded 600 million, while there are approximately 200,000 physical outlets of traditional banks. These 600 million smart phones will become the new point of contact in the financial services sector. Everyone is jumping on the P2P bandwagon: private equity firms, venture capitalists, companies like Lenovo, Xiaomi and other Internet giants as well as traditional companies with physical capital and even Hong Kong developer SHK. With the advent of the big data era, personal credit information systems will gradually improve, and with these information sharing systems freely accessible, P2P will continue to grow. Such cooperation will bring an additional revenue stream to the company as P2P markets grow and expand. The beauty of this cooperation is the ability to leverage ChinaNet’s existing resources, which produce daily sales leads that yield potential borrowers.”

About Yooli

Founded in 2012 by a group of finance and technology professionals, the Company’s goal is to become the leading crowd-funding Web site in China. Yooli is a P2P (person-to-person) online crowd-funding platform that provides financial products for Chinese microfinance investors. Individual borrowers or small business owners can submit loan applications on Yooli.com and, once approved, the applications are posted for lenders review. Borrowers pay interest on monthly basis upon receipt of the loan. (www.yooli.com)

About Haodai

Based in Beijing, Haodai offers a credit product search engine that makes it possible to identify the best loan channels and match banks and financial institutions with borrowers. Users submit a brief application and are contacted by consultants who review their needs and create customized lending solutions. The Company has facilitated approximately $16.33 million in loans, and works with more than 3000 lenders across China. (www.haodai.com)

About ChinaNet Online Holdings, Inc.

The Company, a parent company of ChinaNet Online Media Group Ltd., incorporated in the BVI (“ChinaNet”), is a leading digital B2B (business to business) Internet technology company focusing on providing RMB sales channel expansion service for small and medium-sized enterprises (SMEs) and entrepreneurial management and networking service for entrepreneurs in China. The Company, through certain contractual arrangements with operating companies in the PRC, provides Internet advertising and other services for Chinese SMEs via its portal websites, 28.com, Liansuo.com and Chuangye.com, TV commercials and program production via China-Net TV, and in-house LCD advertising on banking kiosks targeting Chinese banking patrons. Website: http://www.chinanet-online.com.

Safe Harbor

This release contains certain “forward-looking statements” relating to the business of ChinaNet Online Holdings, Inc., which can be identified by the use of forward-looking terminology such as “believes,” “expects,” “anticipates,” “estimates” or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including business uncertainties relating to government regulation of our industry, market demand, reliance on key personnel, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission. These forward-looking statements are based on ChinaNet’s current expectations and beliefs concerning future developments and their potential effects on the Company. There can be no assurance that future developments affecting ChinaNet will be those anticipated by ChinaNet. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of the Company) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. ChinaNet undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.

CONTACT: MZ North America
         Ted Haberfield, President
         Direct: +1-760-755-2716
         Email: thaberfield@mzgroup.us
         Web: www.mzgroup.us

(AEMD) Announces First Treatment of an Ebola Patient

SAN DIEGO, Oct. 14, 2014  — Aethlon Medical, Inc. (NASDAQ:OTCQB:AEMD), announced today the first use of Hemopurifier® therapy on a patient infected with Ebola virus.  The treatment was administered to a Ugandan doctor at the Frankfurt University Hospital in Germany.  The patient, who is also a World Health Organization (WHO) worker, contracted the virus in Sierra Leone.

The Aethlon Hemopurifier® is a first-in-class bio-filtration device that targets the rapid elimination of viruses and immunosuppressive proteins from the circulatory system of infected individuals. At present, no antiviral therapy or vaccine has proven to be effective against Ebola virus infection in humans.  The largest ebola virus epidemic in history is now spreading on a global basis with more than 4,000 deaths being reported by the WHO.

“We thank the physicians in Frankfurt for allowing us the opportunity to treat this advanced-stage patient,” stated Aethlon founder and CEO, Jim Joyce.  “Details related to the patient’s response to therapy will be disclosed once hospital officials deem it appropriate to report an update on the condition of this individual.”

In the care of ebola-infected individuals, the Hemopurifier targets two unmet medical needs: the rapid elimination of circulating ebola to inhibit continued progeny virus replication and the direct targeting of shed glycoproteins that overwhelm the host immune response.  The device can be deployed for use within the global infrastructure of dialysis and CRRT machines already located in hospitals and clinics.

Aethlon further disclosed that it is preparing to initiate U.S. clinical studies of Hemopurifier therapy based on the United States Food and Drug Administration’s (FDA) approval of an Investigational Device Exemption (IDE) that was previously submitted by the Company.  The study will contribute safety data to advance the device as a broad-spectrum countermeasure against pandemic threats, including ebola and chronic viral pathogens such as HIV and Hepatitis C (HCV).

To date, Hemopurifier therapy has been successfully administered in approximately one hundred treatment experiences in health compromised HIV and HCV infected individuals. These studies were conducted at the Apollo Hospital, Fortis Hospital, Sigma New Life Hospital, and the Medanta Medicity Institute, all located in India.  In vitro validation studies that demonstrated the ability of the Hemopurifier to capture Zaire and other strains of ebola virus were conducted by researchers at the United States Army Medical Research Institute for Infectious Diseases (USAMRIID) and the United States Centers for Disease Control and Prevention (CDC).

About Aethlon Medical, Inc.

Aethlon Medical creates medical devices that target unmet therapeutic needs in infectious disease, cancer and neurodegenerative disorders.  The company’s lead product is the Aethlon Hemopurifier®, a first-in-class device that selectively targets the rapid elimination of circulating viruses and tumor-secreted exosomes that promote cancer progression.  Exosome Sciences, Inc. is a majority owned subsidiary that is advancing exosome-based products to diagnose and monitor cancer, infectious disease and neurological disorders.  For more information, please visit http://www.aethlonmedical.com/ and connect with the Company on Twitter, LinkedIn, Facebook and Google+.

Certain statements herein may be forward-looking and involve risks and uncertainties.  Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such potential risks and uncertainties include, without limitation, that the ESI will not be able to commercialize its future products, that the FDA will not approve the initiation of the Company’s clinical programs or provide market clearance of the company’s products, future human studies whether revenue or non-revenue generating of the Aethlon ADAPT™ system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer or hepatitis C therapies or as a standalone cancer or hepatitis C therapy or as a broad spectrum defense against viral pathogens, including ebola, the Company’s ability to raise capital when needed, the Company’s ability to complete the development of its planned products, the Company’s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company’s proprietary technology, the ability of the Company to meet the milestones contemplated in the DARPA contract, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company’s Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts:
James A. Joyce
Chairman and CEO
(Office) 858.459.7800 x301
(Cell) 619-368-2000
jj@aethlonmedical.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

(MMRF) Launches Television Advertising for Interoperable Personal Health Record

(MTVX) To Debut Seven New Products at 2014 AIMExpo

KANSAS CITY, Mo., Oct. 13, 2014  — APT MotoVox Group, Inc. (OTC BB: MTVX) is preparing to make a scene in four days at the 2014 American International Motorcycle Expo (AIMExpo) in Orlando, Florida, America’s No. 1 motorcycle show.  For the first time ever, the company will be presenting seven all-new recreational and light transportation models from its new product lines.

Troy Covey, president of APT, said that company leadership believes that their presentation will be remembered for years to come.  “The motorsport industry is due for a change,” he said.  “The model is old and in many ways broken.  The industry needs something fresh in presentation and product.  We are going to give it to them.”

Covey added, “Nearly 400 international and domestic dealers have already made contact with us to discuss distribution.  That’s an impressive number.  This is a clear indication of the extraordinary interest and continues to validate our projected growth plan for 2015.”

APT will have the attention of over 3,400 dealers and tens of thousands of consumers at the AIMExpo, which will run from Oct. 16-17 for dealers and Oct. 18-19, 2014 for consumers.  At Booth 771, APT will have its complete family line of APT MotoVox, Pro, Motopeds, and SmartCarb technologies.  In addition, APT will transform Booth 2385 into the Motoped Zombie Survival Zone, where dealers and consumers alike can register to win a free Motoped and play interactive zombie games.

APT is also hosting a happy hour for the 3,400 dealers in attendance as well as co-sponsors of the show on Thursday, Oct. 16, 2014 from 6-8 p.m.

About APT MotoVox Group, Inc.:

APT MotoVox Group, Inc. (OTC BB: MTVX) is a Delaware registered corporation headquartered in Kansas City and is the holding company for the MotoVox® and MOTOPED® motorsport product lines, SmartCarb® patented fuel system, and the Sonic Flow small engine technology lines (http://www.motovox.com/, http://www.powerapt.com/ and http://www.motoped.com).

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as “anticipate,” “believe,” “expect,” “future,” “intend,” “plan,” and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry and the Company’s performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company’s public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company’s past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

Contact

William Maher, SVP
APT MotoVox Group, Inc.
InvRel@motovox.com

Paul Knopick
E & E Communications
940.262.3584
pknopick@eandecommunications.com

(REVO) Board Approves $7.0 Million Share Buyback Plan

$7.0 Million Repurchase Price Represents Nearly 10 Times the Current Share Price

CHARLOTTE, N.C., Oct. 13, 2014  — Revolutionary Concepts Inc., (OTCPINK:REVO), a publicly traded company that develops mobile video software and remote security communication systems, announced its Board of Directors has approved the repurchase of up to 140 million shares of its outstanding shares of common stock for a repurchase price of up to $7.0 million to boost shareholder value.

The Board of Directors has approved the repurchase of up to 20% or 140 million of its total outstanding shares. The main purpose of the repurchase plan is the return of capital to the shareholders, reduce the amount of outstanding shares and to improve the companies the capital structure. The repurchase of up to 140 million shares of stock at up to $7.0 million reflects a repurchase price of up to $0.05 per share, or nearly 10 times the current share price.

REVO’s Senior Vice President, Solomon Ali states, “We feel excited about the repurchase of up to $7 million of our shares, as this reflects a repurchase price of up to $0.05 per share, which is almost 10 times the current share price of our stock. We are very positive about the future of REVO, as we are forecasting that $60 to $80 million in estimated annual revenues from licensing fees and royalties could be generated from our global licensing agreement. In September, our global licensee filed complaints in the United States District Court against four companies for allegations of patent infringement against REVO’s intellectual property. All of this is welcome news that could work to the benefit of the Company and its shareholders.”

The Company may buy shares on the open market or in privately negotiated purchases. The timing and amount of any shares repurchased will be determined based on the Company’s evaluation of market conditions, stock price, corporate and regulatory requirements, economic conditions and other factors. Repurchases will be made in compliance with all SEC rules and other legal requirements and may be made in part under a Rule 10b5-1 plan, which permits stock repurchases when the Company might otherwise be precluded from doing so. Any open market purchases will be conducted in accordance with the limitations set forth in Rule 10b-18 of the Securities and Exchange Commission and other applicable legal requirements.

About Revolutionary Concepts Inc.

REVO’s primary business is the design and development of the “EyeTalk” Communicator technology,  a mobile video, remote smart camera security technology. The system is designed to provide nationwide protection and monitoring of homes and businesses against multiple threats including robbery, fire, theft, burglary and other intrusions through  mobile phones, wireless video and remote smart camera security technology. REVO holds patented and patent pending applications that utilize the technology in medical/healthcare, sporting events, child monitoring and several other key areas. For more information visit www.revolutionaryconceptsinc.com.

For inquiries contact: Media Relations: Solomon Ali at 980-225-5376

Safe Harbor Statement – There are matters discussed in this media information that are forward looking statements within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. Such statements are only forecasts and actual events or results may differ materially from those discussed. For a discussion of important factors which could cause actual results to differ from the forward looking statements, refer to Revolutionary Concepts Inc.’s most recent annual report and accounts and other SEC filings. The company undertakes no obligation to update publicly, or revise, forward looking statements, whether as a result of new information, future events or otherwise, except to the extent legally required.

(NSPH) FDA Clears Additional Viral Targets on Verigene Enteric Pathogens Test

NORTHBROOK, Ill., Oct. 13, 2014  — Nanosphere, Inc. (Nasdaq:NSPH), a company enhancing medicine through targeted molecular diagnostics, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Verigene® Enteric Pathogens Nucleic Acid Test (EP), which now includes additional viral targets, as well as the bacterial and toxigenic targets cleared by FDA earlier this summer.

Verigene EP is a rapid, easy-to-use and cost-effective alternative to traditional stool diagnostics that the Company believes has the potential to deliver clinical, economic and workflow benefits to hospitals and laboratories.

“Rapid diagnostic tests that accurately detect the organisms that cause diarrheal illness have the ability to improve physician decisions regarding patient management,” said Paul A. Granato, PhD, D(ABMM), Director of Microbiology and Scientific Director of Clinical Microbiology at Laboratory Alliance, whose laboratory participated in the Verigene EP clinical trial. “In addition to potentially reducing use of unnecessary or inappropriate antibiotics, these tests can help optimize laboratory staff and budgetary resources by reducing the time and costs associated with working up both negative and positive stool specimens.”

Verigene EP is Nanosphere’s second FDA-cleared test in the area of gastroenteritis, joining the currently marketed Verigene Clostridium difficile Nucleic Acid Test (CDF), which identifies toxigenic C. difficile and differentiates the 027 hypervirulent strain for epidemiological purposes.

“The feedback we’ve received from the medical community regarding our approach to designing Verigene EP to provide clinically actionable results for common community-acquired gastrointestinal infections has been very encouraging,” said Michael McGarrity, Nanosphere’s president and chief executive officer. “We anticipate that the addition of Verigene EP to our infectious disease test menu will provide additional value to our customers and patients.”

Nanosphere’s menu includes five multiplex molecular diagnostic tests performed using the automated, sample-to-result Verigene System that target infections of the bloodstream, respiratory tract and gastrointestinal tract. They include the Verigene Gram-Positive Blood Culture Test (BC-GP), the Verigene Gram-Negative Blood Culture Test (BC-GN), the Verigene Respiratory Virus Plus Test (RV+), Verigene CDF (each of which is FDA-cleared and CE-marked), and now Verigene EP. Nanosphere anticipates CE marking of Verigene EP in early 2015.

About the Verigene® System

The Verigene System uses Nanosphere’s core proprietary gold nanoparticle chemistry to offer highly sensitive, highly specific molecular diagnostic results through low-cost multiplexing. The Verigene System rapidly and accurately detects infectious pathogens and drug resistance markers by targeting conserved genetic regions of a bacterium or virus. Currently, the multiplexed Verigene tests target infections of the bloodstream, respiratory tract and gastrointestinal tract. The information gathered from Verigene test results enables clinicians to make informed patient treatment decisions more quickly, which may result in improved patient outcomes, reduced costs, optimized antibiotic therapy and reduced spread of antibiotic resistance.

About Nanosphere, Inc.

Nanosphere is enhancing medicine through targeted molecular diagnostics that result in earlier disease detection, optimal patient treatment and improved healthcare economics. The Company’s versatile technology platform, the Verigene® System, enables clinicians to rapidly detect the most complex, costly and deadly infectious diseases through a low cost and simple-to-use multiplexed diagnostic test. The combination of this innovative technology and Nanosphere’s customer-driven solutions keeps commitment to the patient at the forefront of its business. Nanosphere is based in Northbrook, IL. Additional information is available at http://www.nanosphere.us.

Except for historical information, the matters discussed in this press release are “forward-looking statements” and are subject to risks and uncertainties. Actual results could differ materially from these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the following: (i) Nanosphere’s ability to develop commercially viable products; (ii) Nanosphere’s ability to achieve profitability; (iii) Nanosphere’s ability to produce and market its products; (iv) Nanosphere’s ability to obtain regulatory approval of its products; (v) Nanosphere’s ability to protect its intellectual property; (vi) competition and alternative technologies; and (vii) Nanosphere’s ability to obtain additional financing to support its operations. Additional risks are discussed in the Company’s current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. The forward-looking statements are made as of the date of this press release, and we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT: Investors:
         Roger Moody, Chief Financial Officer
         847-400-9021
         rmoody@nanosphere.us

         Michael Rice, LifeSci Advisors
         646-597-6979
         mrice@lifesciadvisors.com

         Media:
         Zachary Crowther, Director of Marketing
         847-400-9047
         zcrowther@nanosphere.us

(YEWB) Signs Exclusive Distribution Agreement with Carpal Aid

HARBIN, China, Oct. 13, 2014  — Yew Bio-Pharm Group, Inc. (“Yew Bio” or the “Company”) (OTCBB: YEWB), a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China, today announced a multi-year exclusive distribution agreement with Carpal Aid to distribute its non-invasive medical device “Carpal Aid” for carpal tunnel syndrome throughout China.

Carpal Tunnel Syndrome (CTS) is a common nerve disorder that affects approximately 3 to 6% of adults in the general population, according to American Family Physician, a medical journal. CTS is also a frequent pregnancy complication, with prevalence reported as high as 62%. The most typical symptoms are numbness and tingling in the thumb, index finger, middle finger, and radial half of the ring finger, burning dysesthetic wrist pain, as well as the loss of grip strength and dexterity. As symptoms worsen, decreased grip strength makes it difficult to form a fist, grasp small objects, or perform other manual tasks such as driving and dressing. CTS morbidity continues to increase as a result of higher computer use, driving, and other repetitive hand motion.

Developed to provide functional support and help for hand numbness, Carpal Aid is a single use disposable adhesive strip that creates a bridging action that lifts the skin above the median nerve to relieve pressure. Designed to be light-weight and invisible, the product promotes restful sleep and works on both hands.

“We believe Carpal Aid provides an important effective non-invasive option for those who suffer from this common nerve disorder, fulfilling a unique need as there are no effective non-surgical treatments for carpal tunnel in the market today,” said Mr. Zhiguo Wang, Chairman and Chief Executive Officer of Yew Bio-Pharm Group. “We see a lot of potential for introducing innovative therapies, such as Carpal Aid, through our established distribution network, and look forward to introducing this exceptional product to patients and physicians in China.”

The company is currently working with the SFDA (China Food and Drug Administration) to obtain clearance for Carpal Aid.

ABOUT YEW BIO-PHARM GROUP, INC.

Yew Bio-Pharm Group, Inc., through its operating entity, Harbin Yew Science and Technology Development Co., Ltd. (HDS), is a major grower and seller of yew trees, yew raw materials used in the manufacture of traditional Chinese medicine (TCM) and products made from yew timber in China. Raw material from the species of yew tree that the Company grows contains taxol, and TCM containing yew raw materials has been approved as a traditional Chinese medicine in China for secondary treatment of certain cancers. The Company uses a patented, accelerated growth technology to speed the growth and maturity and commercialization of yew trees and believes that it is one of the few companies possessing a permit to sell them. To learn more, please visit http://www.yewbiopharm.com/.

(KITM) and Future Ads LLC Agree to Merge

-Future Ads Projected EBITDA of $30 million for FYE 2014 -Industry Leader Jared Pobre To Become Chairman of Combined Company -Combined Company to Enjoy Significant Revenue Opportunities and Cost Synergies

JERSEY CITY, N.J. and IRVINE, Calif., Oct. 13, 2014  — Kitara Media Corp. (OTC BB: KITM), a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers (“Kitara”), and Future Ads LLC, an Irvine, California based company in the advertising tech industry with unaudited projected revenues of approximately $90 million and unaudited projected EBITDA of approximately $30 million for the year ending December 31, 2014 (“Future Ads”), today jointly announced that they have entered into definitive agreements to merge their respective companies.

“For many years Future Ads and Kitara Media have delivered on exceptional performance and results for online advertisers and we are excited with the combination of the two companies and teams to further accelerate our products and solutions across mobile, display, video and data. Our assets and teams are complementary and the combination will strengthen our ability to drive outstanding advertiser performance as well as financial results,” said Jared Pobre, Future Ads founder and Chief Executive Officer.

“The online advertising market is craving strong integrated solutions that can provide successful performance across many channels. The combination of Future Ads and Kitara Media will form a powerful online advertising platform to provide superior display and video advertising performance solutions to both advertisers and publishers. We are very excited to bring the talents and passion of the teams together to grow the mutual businesses to the benefit of our customers,” said Bob Regular, Chief Executive Officer of Kitara.

After the transaction, the former members of Future Ads will own 53% of the fully diluted stock of the combined company. In addition, the members of Future Ads will receive cash at closing, deferred consideration that may be in cash or stock and have performance-based EBITDA “earn out” targets that would enable them to receive additional cash or stock consideration over the fiscal years ending 2015 to 2018, as more fully set forth in the definitive agreements. The Future Ads members will execute lock-up agreements alongside existing Kitara board member stockholders and other stockholders. Future Ads currently has no existing bank debt or long-term liabilities on its balance sheet.

Kitara has received a fully committed debt facility from a nationally recognized lender that is subject only to the execution of definitive loan documents and satisfaction of closing conditions.

Upon consummation of the transactions, Jared Pobre will become Chairman of the Board of the combined company and Robert Regular will become Chief Executive Officer of the combined company. The newly combined company intends to apply for a listing on the NASDAQ stock market once it meets all listing criteria. It also intends to change its name in connection with the transaction to reflect the combined companies business’ going forward.

The parties will seek to consummate the transactions by December 31, 2014. The transaction is subject to the satisfaction of customary closing conditions. There can be no assurance that a closing will occur.

Complete details and terms of the transaction, including the loan terms, will be contained in a Current Report on Form 8-K to be filed by Kitara on Tuesday due to the Columbus Day federal holiday closing of the Securities and Exchange Commission today.

Gibson, Dunn & Crutcher, LLP represented Future Ads in the transaction. Graubard Miller represented Kitara in the transaction.

About Kitara Media

Kitara Media is a leading digital media and technology company providing video solutions to advertisers, digital marketers and publishers. With nearly 500 million monthly video ad views, Kitara Media delivers strong engagement for advertisers, high revenues for publishers, as well as improved user experience with PROPEL+, an internally developed proprietary video ad technology platform. Kitara Media owns and operates several online media sites including Healthguru.com and Adotas.com. The company is headquartered in Jersey City, NJ. For more information visit http://www.kitaramedia.com.

About Future Ads

Future Ads is a digital media platform for results-focused online advertising and publisher monetization. Future Ads’ innovative, diversified solutions works synergistically to help advertisers and publishers achieve outstanding performance results. Founded in 2001, Future Ads is headquartered in Irvine, CA. For more information, visit http://www.futureads.com.

Forward Looking Statements 

This press release includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of Kitara’s and Future Ads’ management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements.

Forward-looking statements are inherently uncertain and subject to a variety of events, factors and conditions, many of which are beyond the control of Kitara and Future Ads and not all of which are known to Kitara or Future Ads, including, without limitation those risk factors described from time to time in Kitara’s reports filed with the SEC.  Among the factors that could cause actual results to differ materially are: loss of key advertising customers; inability to acquire new advertising customers; inability to expand video content library; inability to achieve projected results; inability to protect intellectual property; inability to execute acquisition strategy; inability to effectively manage growth; failure to effectively integrate the operations of acquired businesses; competition; loss of key personnel; increases in costs of operations; continued compliance with government regulations; general economic conditions; and the possibility that the transaction does not close due to the failure to achieve the necessary closing conditions. Most of these factors are outside the control of Kitara and Future Ads and are difficult to predict. The information set forth herein should be read in light of such risks. Further, investors should keep in mind that the financial results included herein are unaudited, contain certain non-GAAP measures and may not conform to SEC Regulation S-X.  As a result, such information may be presented differently in Kitara’s periodic filings with the Securities Exchange Commission and may fluctuate materially depending on many factors. Accordingly, the financial results in any particular period may not be indicative of future results. Neither Kitara nor Future Ads assumes any obligation to update the information contained in this press release except as required by law.